152 related articles for article (PubMed ID: 38195325)
21. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
22. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
23. [Chronic myeloid leukemia: aiming for treatment free remission].
Kimura S
Rinsho Ketsueki; 2021; 62(6):572-581. PubMed ID: 34219083
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
26. Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia.
Kim E; Hwang EJ; Lee J; Kim DY; Kim JY; Kim DW
Neoplasia; 2022 Oct; 32():100817. PubMed ID: 35878453
[TBL] [Abstract][Full Text] [Related]
27. Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Kong JH; Winton EF; Heffner LT; Chen Z; Langston AA; Hill B; Arellano M; El-Rassi F; Kim A; Jillella A; Kota VK; Bodó I; Khoury HJ
Cancer; 2017 Jul; 123(13):2482-2488. PubMed ID: 28241101
[TBL] [Abstract][Full Text] [Related]
28. Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Slezáková K; Mistrík M; Bátorová A
Vnitr Lek; 2020; 66(4):214-224. PubMed ID: 32972178
[TBL] [Abstract][Full Text] [Related]
29. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial.
Flygt H; Söderlund S; Richter J; Saussele S; Koskenvesa P; Stenke L; Mustjoki S; Dimitrijevic A; Stentoft J; Majeed W; Roy L; Wolf D; Dreimane A; Gjertsen BT; Gedde-Dahl T; Ahlstrand E; Markevärn B; Hjorth-Hansen H; Janssen J; Olsson-Strömberg U
Leukemia; 2024 Apr; 38(4):781-787. PubMed ID: 38278960
[TBL] [Abstract][Full Text] [Related]
30. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
31. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
32. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.
Rios SJ; Martínez-Montesinos L; Aroca C; Teruel-Montoya R; Ferrer-Marín F
J Assist Reprod Genet; 2020 Oct; 37(10):2473-2476. PubMed ID: 32766925
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
34. [Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy].
Turkina AG; Chelysheva EY; Shuvaev VA; Gusarova GA; Bykova AV; Shukhov OA; Petrova AN; Vakhrusheva MV; Goryacheva SR; Kolosova LY; Krasikova PS; Fominykh MS; Martynkevich IS; Abdullaev AO; Sudarikov AB; Savchenko VG
Ter Arkh; 2017; 89(12):86-96. PubMed ID: 29411766
[TBL] [Abstract][Full Text] [Related]
35. Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Li N; Yang X; Fan L; Totev T; Guerin A; Chen L; Bhattacharyya S; Joseph G
J Med Econ; 2017 Apr; 20(4):328-336. PubMed ID: 27841717
[TBL] [Abstract][Full Text] [Related]
36. Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Ureshino H; Kamachi K; Sano H; Okamoto S; Itamura H; Yoshimura M; Katsuya H; Ando T; Kimura S
Hematology; 2022 Dec; 27(1):1171-1175. PubMed ID: 36326484
[TBL] [Abstract][Full Text] [Related]
37. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
38. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
40. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]